S
Stephen W. Fesik
Researcher at Vanderbilt University
Publications - 298
Citations - 42613
Stephen W. Fesik is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Nuclear magnetic resonance spectroscopy & Binding site. The author has an hindex of 95, co-authored 294 publications receiving 40006 citations. Previous affiliations of Stephen W. Fesik include Howard Hughes Medical Institute & Yale University.
Papers
More filters
Journal ArticleDOI
Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors.
Bin Zhao,Allison L. Arnold,Marcelle A Coronel,Joyce H Lee,Taekyu Lee,Edward T. Olejniczak,Stephen W. Fesik +6 more
TL;DR: To test for on target toxicity of a new chemical entity, it is important to have comparable binding affinities of the compound in the target proteins from humans and the test species, and to evaluate the myeloid cell leukemia-1 (Mcl-1) inhibitors, they were tested against rodent MCl-1 and found a significant loss of binding affinity.
Journal ArticleDOI
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
Andrea C. Florian,Chase M Woodley,Jing Wang,Brian C. Grieb,Macey J Slota,Kiana Guerrazzi,Chih-Yuan Hsu,Brittany K. Matlock,David K. Flaherty,Shelly L. Lorey,Stephen W. Fesik,Gregory C. Howard,Qi Liu,April M. Weissmiller,William P. Tansey +14 more
TL;DR: A p53-independent action of WIN site inhibitors is revealed and it is forecast that future strategies to treat RT could be based on dual WDR5/HDM2 inhibition.
Journal ArticleDOI
The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice.
Alex R. Shoemaker,Michael J. Mitten,Jessica Adickes,Anatol Oleksijew,Haichao Zhang,Joy Bauch,Kennan C. Marsh,David Frost,David Madar,Christin Tse,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +12 more
TL;DR: The results showed a rapid, dose-dependent reduction in circulating platelet counts with a platelet nadir (>80% reduction relative to baseline) occurring approximately 6 hours after a single 100 mg/kg oral dose of ABT-263.
Journal ArticleDOI
Preparation of biologically active ristocetin derivatives: replacements of the 1′-amino group
TL;DR: A series of ristocetin analogues with modifications at the C-1' amino group was synthesized and found to possess antibacterial activity against gram-positive bacteria and to bind to Ac2-Lys-D-Ala-DAla, a model for the antibiotic's site of action as discussed by the authors.